2012 in BPH has been characterized by studies investigating treatment options for BPH-associated lower urinary tract symptoms (LUTS). Onabotulinumtoxin A and saw palmetto have both been shown to be no more effective than placebo. However, in a positive move, tadalafil received FDA approval for LUTS treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Avins, A. L. et al. Safety and Toxicity of Saw palmetto in the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Trial. J. Urol. http://dx.doi.org/10.1016/j.juro.2012.10.002.
Barnes, J. Saw palmetto. Serenoa repens. Also known as Serenoa serrulata, Sabal serrulata and the dwarf palm. J. Prim. Health Care 1, 323 (2009).
Bent, S. et al. Saw palmetto for benign prostatic hyperplasia. N. Engl. J. Med. 354, 557–566 (2006).
Helfand, B. T. et al. Associations Between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS Trial. J. Urol. 188, 2288–2293 (2012).
Marberger, M. et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2012.10.005.
Cohen, P. G. Intra-abdominal pressure, LUTS, and tadalafil. Re: Andersson K-E. et al. tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol urodyn 2011;30, 292–301. Neurourol. Urodyn. 31, 706 (2012).
Warde, N. Therapy: two birds, one stone: tadalafil is an effective treatment for men with both BPH-LUTS and ED. Nat. Rev. Urol. 8, 643 (2011).
Gomelsky, A. & Dmochowski, R. R. Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Curr. Urol. Rep. 11, 254–260 (2010).
Bechara, A. et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J. Sex. Med. 5, 2170–2178 (2008).
Gacci, M. et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 61, 994–1003 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Chughtai, B., Te, A. Novel agents in treatment of BPH. Nat Rev Urol 10, 72–73 (2013). https://doi.org/10.1038/nrurol.2012.250
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.250
